GEO DataSets

(Submitter supplied) Background: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30-40% of ER+BC will relapse despite tamoxifen treatment. New prognostic biomarkers and further biological understanding of tamoxifen resistance are required. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

77 Samples

Download data: CEL, RDATA, TXT

(Submitter supplied) Purpose: A number of microarray studies have reported distinct molecular profiles of breast cancers (BC): basal-like, ErbB2-like and two to three luminal-like subtypes. These were associated with different clinical outcomes. However, although the basal and the ErbB2 subtypes are repeatedly recognized, identification of estrogen receptor (ER)-positive subtypes has been inconsistent. Refinement of their molecular definition is therefore needed. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platforms:

GPL96 GPL97 GPL570

741 Samples

Download data: CEL, RDATA, TXT

(Submitter supplied) dataset of 60 patients with ER-positive primary breast cancer and treated with tamoxifen monotherapy for 5 years. Data were generated from LCMed cancer cells. Sample_keyword: breast cancer, tamoxifen, recurrence Keywords: other

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS807

Platform:

GPL1223

60 Samples

Download data

Expression profiling of microdissected estrogen positive primary breast cancer tumors from 60 patients. Patients later treated with tamoxifen for 5 years, and tumors grouped according to whether cancer recurred. Results identify markers of disease-free survival that include HOXB13 and IL17BR.

Organism:

Homo sapiens

Type:

Expression profiling by array, log ratio, 2 disease state sets

Platform:

GPL1223

Series:

GSE1378

60 Samples

Download data